Sequent Scientific Limited (SEQUENT.NS)
Sequent Scientific Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Mumbai, IN. The stock last traded at $202.40, down 0.78% on the session, giving a market capitalisation of $50.56B. Its beta of 0.96 implies it has historically moved less than the broad market.
Operating on a global scale, Sequent Scientific Limited specializes in the animal health sector. The company supplies both active pharmaceutical ingredients (APIs) and formulated products for animals, addressing a diverse range of therapeutic needs. These offerings encompass anthelmintics (including treatments for internal and external parasitic infections), anti-protozoal agents, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives, and dermatological solutions. Furthermore, Sequent Scientific provides extensive analytical services that support organizations across the API, pharmaceutical, personal care, and nutraceutical industries. These services feature method validation, stability assessments, and microbiological testing for both active ingredients and final products. Established in 1985 and headquartered in Mumbai, India, the firm was previously known as PI Drugs and Pharmaceuticals Limited and currently operates as a subsidiary of CA Harbor Investments.
Sequent Scientific Limited is most often compared with the following Healthcare names: